Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.


Creative Commons License

Ulas A., Kos T., Avci N., Cubukcu E., Olmez O. F., Bulut N., ...Daha Fazla

Asian Pacific journal of cancer prevention : APJCP, cilt.16, ss.1643-9, 2015 (SCI-Expanded) identifier identifier